圣达生物(603079) - 2025 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2025 was CNY 203,225,651.02, representing a year-on-year increase of 9.95% compared to CNY 184,829,589.97 in the same period last year[4]. - Net profit attributable to shareholders of the listed company reached CNY 21,709,484.85, a significant increase of 469.35% from CNY 3,813,060.72 in the previous year[4]. - The basic and diluted earnings per share were both CNY 0.13, reflecting a 550.00% increase from CNY 0.02 in the same period last year[5]. - The weighted average return on equity increased by 1.4 percentage points to 1.71% compared to 0.31% in the previous year[5]. - Total revenue for Q1 2025 reached ¥203,225,651.02, an increase of 9.5% compared to ¥184,829,589.97 in Q1 2024[20]. - Net profit for Q1 2025 was ¥23,418,911.36, significantly up from ¥5,303,881.02 in Q1 2024, representing a growth of 341.5%[21]. - Operating profit for Q1 2025 was ¥27,633,346.93, compared to ¥7,505,502.29 in Q1 2024, indicating a substantial increase[21]. - Basic earnings per share for Q1 2025 were ¥0.13, compared to ¥0.02 in Q1 2024, indicating a significant improvement[22]. Cash Flow and Assets - The net cash flow from operating activities was negative at CNY -21,121,737.08, worsening from CNY -7,787,016.92 in the same period last year[4]. - Cash flow from operating activities was ¥190,106,736.12 in Q1 2025, up from ¥178,966,766.36 in Q1 2024, reflecting a growth of 6.3%[24]. - The total cash outflow from operating activities was $228,918,640.38, compared to $198,347,829.36 previously, resulting in a net cash flow from operating activities of -$21,121,737.08, worsening from -$7,787,016.92[25]. - The company's current assets totaled approximately 663.38 million RMB, a decrease from 708.77 million RMB on December 31, 2024[15]. - The company's cash and cash equivalents decreased from approximately 315.62 million RMB to 244.56 million RMB over the same period[15]. - The ending cash and cash equivalents balance was $222,366,162.95, down from $247,275,484.71, reflecting a decrease of approximately 10.1%[26]. Investments and Fundraising - The company plans to issue up to 51,356,687 A-shares, raising a total of no more than 500 million RMB, to invest in the production of 3 billion soft capsules and 3 billion solid preparations, as well as a project for an annual output of 20,000 tons of D-isoascorbic acid and its sodium salt[13]. - The company has adjusted its fundraising amount for the A-share issuance from 500 million RMB to 267.61 million RMB[13]. - Cash inflow from investment activities totaled $88,480,311.40, significantly up from $23,717,143.12, indicating a substantial increase in investment recovery[25]. - The cash outflow from investment activities was $131,675,436.43, compared to $108,287,452.50, leading to a net cash flow from investment activities of -$43,195,125.03, an improvement from -$84,570,309.38[25]. Shareholder Information - The major shareholders include Zhejiang Shengda Group Co., Ltd. with a 26.51% stake and Tian Tai Wan Jian Investment Development Center with an 18.28% stake[10]. - The employee stock ownership plan aims to hold up to 872,500 shares, with a total funding not exceeding 4.9995 million RMB[14]. - The stock purchase price for the employee stock ownership plan is set at 5.73 RMB per share[14]. - The company has not yet implemented the employee stock ownership plan as of March 31, 2025[14]. Research and Development - Research and development expenses rose to ¥10,162,625.24 in Q1 2025, up from ¥7,896,868.68 in Q1 2024, reflecting a 28.7% increase[21]. - The company has not disclosed any new product developments or market expansion strategies in this report[8]. Asset Changes - The total assets at the end of the reporting period were CNY 1,806,478,130.51, a slight increase of 1.19% from CNY 1,785,311,152.08 at the end of the previous year[5]. - The company’s fixed assets decreased slightly from approximately 432.02 million RMB to 424.76 million RMB[16]. - The company’s intangible assets increased from approximately 225.58 million RMB to 227.64 million RMB[16]. - Total liabilities decreased to ¥499,084,898.78 from ¥501,336,831.71, showing a reduction of 0.5%[18]. - Shareholders' equity increased to ¥1,307,393,231.73 from ¥1,283,974,320.37, marking a growth of 1.8%[18].